Tadalafil: A novel treatment for erectile dysfunction

European Heart Journal, Supplement

Volumn 4, Issue H, 2002, Pages

  Giuliano, François ^a   Varanese, L ^b  

^a BICÊTRE HOSPITAL   (France)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes; Efficacy; Erectile dysfunction; Pharmacodynamics; Pharmacokinetics; Safety; Tadalafil

Indexed keywords

PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PLACEBO; TADALAFIL; UNCLASSIFIED DRUG;

ADULT; AGE; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; BACKACHE; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RHINITIS; SEXUAL INTERCOURSE;

EID: 0036893163     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90049-0     Document Type: Review

References (26)

1. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-236.
2. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavemosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843-50.
3. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavemosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-4.
4. Trigo-Rocha F, Aronson WJ, Hohenfellner M, Ignarro LJ, Rajfer J, Lue TF. Nitric oxide and cGMP: Mediators of pelvic nervestimulated erection in dogs. Am J Physiol 1993; 264: H419-22.
5. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
6. Burls A, Gold L, Clark W. Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction. Br J Gen Pract 2001; 51: 1004-12.
7. Langtry HD, Markham A. Sildenafil: A review of its use in erectile dysfunction. Drugs 1999; 57: 967-89.
8. Palumbo F, Bettocchi C, Selvaggi FP, Pryor JP, Ralph DJ. Sildenafil: Efficacy and safety in daily clinical experience. Eur Urol 2001; 40: 176-80.
9. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999; 54: 1073-7.
10. Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2-9.
11. Padma-Nathan H, Giuliano F. Oral drug therapy for erectile dysfunction. Urol Clin North Am 2001; 28: 321-34.
12. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001; 13: 192-9.
13. Noto T, Inoue H, Ikeo T, Kikkawa K. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs. J Pharmacol Exp Ther 2000; 294: 870-5.
14. Oh TY, Kang KK, Ahn BO, Yoo M, Kim WB. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2000; 23: 471-6.
15. Rotella DP, Sun Z, Zhu Y, et al. N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. J Med Chem 2000; 43: 1257-63.
16. Takagi M, Mochida H, Noto T, et al. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavemosum. Eur J Pharmacol 2001; 411: 161-8.
17. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. Dosenormalized pharmacokinetics of single-dose tadalafil (IC351) in healthy volunteers [abstract 14]. Int J Impot Res 2001; 13(suppl 5): S63.
18. Patterson B, Bedding A, Jewell H, Payne C, Mitchell MI. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351) [abstract 16]. Int J Impot Res 2001; 13(suppl 5): S62.
19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
20. Brock GE, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002; 168: 1322-6.
21. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-51.
22. Padma-Nathan H, Rosen RC, Shabsigh R, Saikali K, Watkins V. Tadalafil (IC351) provides prompt and extended period of response for the treatment of men with ED [abstract 20]. Int J Impot Res 2001; 13(suppl 5): S64.
23. Porst H, Rosen RC, Padma-Nathan H, Varanese L, Anglin G. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose [abstract 709]. J Urol 2002; 167(suppl): 177.
24. Lewis R, Hatzichristou D, Laumann E, McKinlay J. Epidemiology and natural history of erectile dysfunction. In: Jardin A, Wagner G, Khoury S, et al., eds. First International Consultation on Erectile Dysfunction, July 1-3, 1999. Plymouth: Health Publications Ltd; 2000: 19-52.
25. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: Association with glycemic control. J Urol 2000; 163: 788-91.
26. Sáenz de Tejada I, Anglin G, Knight J, Emmick J. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002 (in press).